GlaxoSmithKline plc (LON:GSK) had its price objective lowered by J P Morgan Chase & Co from GBX 1,750 ($22.60) to GBX 1,570 ($20.28) in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Bryan, Garnier & Co reiterated a buy rating and set a GBX 1,750 ($22.60) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, May 31st. UBS AG set a GBX 1,600 ($20.66) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research report on Monday, May 29th. Goldman Sachs Group, Inc. (The) reiterated a buy rating and set a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, May 31st. Liberum Capital reiterated a buy rating and set a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, June 14th. Finally, Deutsche Bank AG reiterated a hold rating and set a GBX 1,720 ($22.21) price target on shares of GlaxoSmithKline plc in a research report on Friday, June 30th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. GlaxoSmithKline plc presently has a consensus rating of Hold and a consensus price target of GBX 1,705.90 ($22.03).

Shares of GlaxoSmithKline plc (GSK) opened at 1454.00 on Wednesday. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56. The firm’s market capitalization is GBX 71.07 billion. The company’s 50-day moving average is GBX 1,507.18 and its 200 day moving average is GBX 1,610.52.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/16/glaxosmithkline-plc-gsk-pt-lowered-to-gbx-1570-at-j-p-morgan-chase-co.html.

The company also recently declared a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other news, insider Patrick Vallance purchased 861 shares of the company’s stock in a transaction on Friday, July 14th. The shares were purchased at an average cost of GBX 1,618 ($20.90) per share, with a total value of £13,930.98 ($17,991.71). Also, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.86), for a total transaction of £81,602.60 ($105,388.87). Insiders have acquired 3,152 shares of company stock worth $5,055,023 over the last ninety days.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.